Summary by Moomoo AI
CKLife sciences announced its interim report for 2024, with unaudited shareholders' profit of approximately HKD 1 million, a decrease of 97% compared to the same period last year. The company announced that it will not distribute interim dividends and is expected to record approximately AUD 8.2 million in proceeds from the sale of the Balranald vineyard land and water permit in Australia after the settlement date. CKLife sciences focuses on the research and development of cancer therapies and early cancer detection programs, and invests in the cancer diagnostics company Pharus to develop liquid biopsy technology. The company's health product business performed steadily, with a profit of HKD 156.4 million. However, the continued impact of inflation rates is putting pressure on cost composition. CKLife sciences will continue to make stable investments in the field of medical and diagnostic research, and is expected to expand the investment scale in the research field.
